Physician profile

Steven K Hata

Neurology (Psychiatry & Neurology) · Rapid City, SD

NPI 1003966334

$407.01

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$20.47

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Greenwich Biosciences, INC. $125.00 2020
Medtronic, INC. $76.03 2022-2023 Corevalve Evolut R
Abbvie INC. $53.84 2022
Supernus Pharmaceuticals, INC. $28.59 2019
Acadia Pharmaceuticals INC $27.60 2020
Novartis Pharmaceuticals Corporation $24.26 2019
Genzyme Corporation $19.65 2020
Ge Healthcare $19.44 2020
Sk Life Science, INC. $18.52 2022
Livanova USA, INC. $14.08 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Steven K Hata

$407.01

in general payments reported 2019-2025

Years
2019-2023
Top company
Greenwich Biosciences, INC.

https://glasscript.com/doctor/91041/steven-k-hata

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.